Overview

BAY14-2222 Continuous Infusion in Surgeries

Status:
Completed

Trial end date:
2005-05-01

Target enrollment:

Participant gender:

Summary

Phase III study, to evaluate the efficacy and safety of continuous infusion of rFVIII-FS in the treatment of patients with hemophilia A undergoing major elective surgery by achieving the required therapeutic concentrations.

Phase:

Phase 3

Details

Lead Sponsor:

Bayer

Treatments:

Factor VIII